ABSTRACT SUBMISSION

The International Society of Pharmacovigilance (ISoP) invites you to submit your abstracts for the 25th ISoP Global Meeting, taking place in San José, Costa Rica, 22–25 September 2026.

Under the theme:
“Ecosystems of Trust: Pharmacovigilance for a Healthier World”,
this milestone meeting will bring together global experts, regulators, industry leaders, academics, healthcare professionals, and patients to advance medicines safety worldwide.

 

Abstract Guidelines

Abstracts are summaries of the overall goal of an offering and the specific ideas or concepts that will be presented, including outcomes and implications for practice. 

Please limit abstracts to a 450-word count; this does not include the title or the author block, which is entered in a different field of the submission process.

Abstracts must be submitted only in English consisting of five sections with the following headings:

• Introduction

• Objective

• Methods

• Results

• Conclusion

• References/Further sources of information

Abstracts should be submitted using the online submission system before the submission deadline of 20th of April, 2026. After the submission deadline, all abstracts will be automatically considered to be fully submitted and will proceed to the peer review.

Up to 15 authors can be submitted for an abstract (including the presenting author). The presenting author is selected first; other authors can be added only when the presenting author is submitted. However, the author order can be changed if needed by swapping the names in the list of the authors.  The first name is always considered to be the main author, and the presenting author should be marked.

All accepted abstracts will be published in Drug Safety, the ISoP official journal. It is highly recommended to check the abstract for correct spelling, punctuation, grammar, and formal structure before submitting.

Please check that references are cited in the text. There is a possibility that references will be deleted during production if they are not cited in the text.

If necessary, the editor (s) of Drug Safety Journal reserve the right to edit abstracts.

This year’s Meeting intends to provide original and high-quality sessions focused on educational content that is free from commercial influence or bias. We request all presenters to cooperate with this by declaring during the abstract submission process that the abstract is unpublished and original material, and fill the conflict of interest form.